@article{3219603,
    title = "Artificial intelligence supporting cancer patients across Europe—The ASCAPE project",
    author = "Tzelves, L. and Manolitsis, I. and Varkarakis, I. and Ivanovic, M. and Kokkonidis, M. and Useros, C.S. and Kosmidis, T. and Muñoz, M. and Grau, I. and Athanatos, M. and Vizitiu, A. and Lampropoulos, K. and Koutsouri, T. and Stefanatou, D. and Perrakis, K. and Stratigaki, C. and Autexier, S. and Kosmidis, P. and Valachis, A.",
    journal = "PLOS ONE",
    year = "2022",
    volume = "17",
    number = "4 April",
    publisher = "Public Library of Science",
    doi = "10.1371/journal.pone.0265127",
    keywords = "Article;  artificial intelligence;  breast cancer;  cancer patient;  cancer rehabilitation;  cancer survivor;  clinical decision support system;  clinical practice;  clinical trial protocol;  clinician;  cohort analysis;  controlled study;  data analysis;  doctor patient relationship;  Europe;  female;  follow up;  health status indicator;  human;  longitudinal study;  male;  medical informatics;  medical record;  patient coding;  patient engagement;  personalized medicine;  prediction;  prospective study;  prostate cancer;  quality of life;  questionnaire;  software;  artificial intelligence;  breast tumor;  prostate tumor, Artificial Intelligence;  Breast Neoplasms;  Humans;  Longitudinal Studies;  Male;  Physician-Patient Relations;  Prostatic Neoplasms;  Quality of Life",
    abstract = "Introduction Breast and prostate cancer survivors can experience impaired quality of life (QoL) in several QoL domains. The current strategy to support cancer survivors with impaired QoL is suboptimal, leading to unmet patient needs. ASCAPE aims to provide personalized- and artificial intelligence (AI)-based predictions for QoL issues in breast- and prostate cancer patients as well as to suggest potential interventions to their physicians to offer a more modern and holistic approach on cancer rehabilitation. Methods and analyses An AI-based platform aiming to predict QoL issues and suggest appropriate interventions to clinicians will be built based on patient data gathered through medical records, questionnaires, apps, and wearables. This platform will be prospectively evaluated through a longitudinal study where breast and prostate cancer survivors from four different study sites across the Europe will be enrolled. The evaluation of the AI-based follow-up strategy through the ASCAPE platform will be based on patients’ experience, engagement, and potential improvement in QoL during the study as well as on clinicians’ view on how ASCAPE platform impacts their clinical practice and doctor-patient relationship, and their experience in using the platform. Ethics and dissemination ASCAPE is the first research project that will prospectively investigate an AI-based approach for an individualized follow-up strategy for patients with breast- or prostate cancer focusing on patients’ QoL issues. ASCAPE represents a paradigm shift both in terms of a more individualized approach for follow-up based on QoL issues, which is an unmet need for cancer survivors, and in terms of how to use Big Data in cancer care through democratizing the knowledge and the access to AI and Big Data related innovations. Trial registration Trial Registration on clinicaltrials.gov: NCT04879563. © 2022 Tzelves et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited."
}